BIOMAT Database Logo BIOMAT Database Logo

Prolongation of canine renal allograft survival by treatment with FK-506. 1987

T Ochiai, and M Nagata, and K Nakajima, and K Sakamoto, and T Asano, and K Isono
Department of Surgery, School of Medicine, Chiba University, Japan.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007273 Injections, Intramuscular Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it. Intramuscular Injections,Injection, Intramuscular,Intramuscular Injection
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D005260 Female Females
D006085 Graft Survival The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host. Graft Survivals,Survival, Graft,Survivals, Graft
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013268 Stimulation, Chemical The increase in a measurable parameter of a PHYSIOLOGICAL PROCESS, including cellular, microbial, and plant; immunological, cardiovascular, respiratory, reproductive, urinary, digestive, neural, musculoskeletal, ocular, and skin physiological processes; or METABOLIC PROCESS, including enzymatic and other pharmacological processes, by a drug or other chemical. Chemical Stimulation,Chemical Stimulations,Stimulations, Chemical

Related Publications

T Ochiai, and M Nagata, and K Nakajima, and K Sakamoto, and T Asano, and K Isono
Prolongation of pancreaticoduodenal allograft survival in rats by treatment with FK 506.
December 1991, Transplantation proceedings,
T Ochiai, and M Nagata, and K Nakajima, and K Sakamoto, and T Asano, and K Isono
Prolongation of canine renal allograft survival by L asparaginase.
September 1971, Transplantation,
T Ochiai, and M Nagata, and K Nakajima, and K Sakamoto, and T Asano, and K Isono
Pathological studies in canine and baboon renal allograft recipients immunosuppressed with FK-506.
October 1987, Transplantation proceedings,
T Ochiai, and M Nagata, and K Nakajima, and K Sakamoto, and T Asano, and K Isono
Prolongation of canine renal allograft survival with antilymphoid antisera.
July 1968, Surgery, gynecology & obstetrics,
T Ochiai, and M Nagata, and K Nakajima, and K Sakamoto, and T Asano, and K Isono
Prolongation of canine renal allograft survival with antilymphocytic serum.
May 1968, Transplantation,
T Ochiai, and M Nagata, and K Nakajima, and K Sakamoto, and T Asano, and K Isono
FK 506 in canine renal transplantation.
October 1992, Transplantation proceedings,
T Ochiai, and M Nagata, and K Nakajima, and K Sakamoto, and T Asano, and K Isono
Reversal of accelerated renal allograft rejection with FK 506.
August 1997, Clinical transplantation,
T Ochiai, and M Nagata, and K Nakajima, and K Sakamoto, and T Asano, and K Isono
Improved renal allograft survival in children treated with FK 506 (tacrolimus) rescue therapy.
December 1996, Pediatric nephrology (Berlin, Germany),
T Ochiai, and M Nagata, and K Nakajima, and K Sakamoto, and T Asano, and K Isono
Prolongation of xenograft survival by combining donor-specific intravenous presensitization with FK 506.
November 2002, Transplantation proceedings,
T Ochiai, and M Nagata, and K Nakajima, and K Sakamoto, and T Asano, and K Isono
Prolongation of canine renal allograft survival by combining tacrolimus with antimetabolic agents.
January 1997, Transplantation proceedings,
Copied contents to your clipboard!